Business
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. “We are thrilled to be joining the Russell 2000® Index, a testament to our Company’s progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “This milestone reflects Capricor’s commitment to developing groundbreaking therapies that make a meaningful impact on patients’ lives. With the addition to these indexes, we look forward to increasing our exposure to the investment community.” The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which lasts for one year, guarantees automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the appropriate growth and value style indexes. FTSE Russell primarily determines index membership based on objective market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.5 trillion in assets are benchmarked against Russell’s U.S. indexes. FTSE Russell, a leading global index provider, administers these indexes. For more information on the Russell 2000® Index and the Russell indexes reconstitution, please visit the Russell Reconstitution Section on the FTSE Russell website. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regen...